ITGAV and SMAD4 influence the progression and clinical outcome of pancreatic ductal adenocarcinoma
Molecular Oncology · 2025
DOI: 10.1002/1878-0261.70080 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, 2025. Verfasst von Daniel K C Lee und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology & Toxicology, University of Toronto, Canada. Hauptthemen laut MEDLINE: Smad4 Protein, Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms, Disease Progression. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CIHR, Temerty Faculty of Medicine, University of Toronto, Canada Foundation for Innovation.
Abstract (Originalsprache)
Pancreatic ductal adenocarcinoma (PDAC) is a very aggressive and lethal malignancy with limited treatment options, a fact that underscores the urgent need for more effective therapies to improve patient outcomes. Preclinical studies have shown promise for αV integrin‐targeted therapies; however, clinical trials have been disappointing, highlighting the need for further research. In this study, we demonstrate that integrin subunit alpha V (ITGAV) signals through both mothers against decapentaplegic homolog 4 (SMAD4)‐dependent or SMAD4‐independent pathways, depending on the genetic context. In SMAD4 ‐positive PDAC cells, ITGAV contributes to the transforming growth factor‐beta (TGF‐β) signaling pathway to regulate proliferation, migration, and invasion. Conversely, in SMAD4 ‐negative PDAC cells, ITGAV influences only proliferation and migration via activation of the mitogen‐activated protein kinase (MAPK)/extracellular signal‐related kinase (ERK) pathway. High levels of ITGAV are also associated with poor prognostic outcomes in SMAD4 wild‐type patients but are not prognostic in SMAD4 mutant patients. Thus, ITGAV contributes to different patterns of PDAC progression. These findings suggest that stratifying PDAC patients based on both SMAD4 status and ITGAV expression could inform more effective integrin‐targeted treatment strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology & Toxicology, University of Toronto, Canada.
- Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.
ORCID-Profile: Xiang Li, Leonardo Salmena
Förderung
- CIHR
- Temerty Faculty of Medicine, University of Toronto
- Canada Foundation for Innovation
- Canadian Institutes of Health Research
Zitieren
APA
Lee, D. K. C., Chen, K., Loke, R., Li, X., Liubart, D., Saffi, G. T., Chow, J. T. S., Melo, C. M. P., To, L., & Salmena, L. (2025). ITGAV and SMAD4 influence the progression and clinical outcome of pancreatic ductal adenocarcinoma. Molecular Oncology. https://doi.org/10.1002/1878-0261.70080
Vancouver
Lee DKC, Chen K, Loke R, Li X, Liubart D, Saffi GT, et al. ITGAV and SMAD4 influence the progression and clinical outcome of pancreatic ductal adenocarcinoma. Molecular Oncology. 2025. doi:10.1002/1878-0261.70080
BibTeX
@article{Lee2025,
author = {Lee, Daniel K C and Chen, Keyue and Loke, Ryan and Li, Xiang and Liubart, David and Saffi, Golam T and Chow, Jonathan T S and Melo, Ché M P and To, Lydia and Salmena, Leonardo},
title = {ITGAV and SMAD4 influence the progression and clinical outcome of pancreatic ductal adenocarcinoma},
journal = {Molecular Oncology},
year = {2025},
doi = {10.1002/1878-0261.70080}
}
EUVIMED